Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00584909 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT00584909 is a Phase 2 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 13 participants.
The verdict
NCT00584909, a Phase 2 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The main purpose of this study us to determine the best treatment for patients with endometrial cancer who are at an elevated risk for recurrence.
Interventions
- DRUG Paclitaxel and carboplatin combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-03 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00584909
The ClinicalTrials.gov registry entry for NCT00584909 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel and carboplatin combination is the first listed.
NCT00584909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00584909 about?
NCT00584909 is a clinical study titled "A Phase II Study of Paclitaxel and Carboplatin in Patients With an Elevated-Risk Cancer of the Uterus". The main purpose of this study us to determine the best treatment for patients with endometrial cancer who are at an elevated risk for recurrence.
What is the current status of trial NCT00584909?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2006-03. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00584909?
The interventions under investigation include: Paclitaxel and carboplatin combination (DRUG).
Who is sponsoring clinical trial NCT00584909?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.